MIPs are nanostructured polymer particles typically containing a single binding site for their target. They can also be fused to solid substrates, such as sensor surfaces. MIP Diagnostics has successfully created and deployed MIPs against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors. MIPs can withstand harsh chemical environments, such as extremes of pH, seawater or high concentrations of organic solvents. They are temperature resistant and have a very long shelf-life without refrigeration.
The global market for antibodies and antibody alternatives is growing rapidly (value is c.£85bn) and has been accelerated by the current COVID19 pandemic, creating a sizeable demand for MIP Diagnostics to apply its innovative approach and depth of expertise within the IVD and life sciences industry. MIP Diagnostics’ nanoMIP format is suitable for a wide range of applications including diagnostics, healthcare and bioprocessing.
There are two key strands to the service MIP Diagnostics offers its clients: reagents for purification and separation and the development of “sensor” MIP reagents. Across both strands of its work, MIP Diagnostics offers both “universal” reagents and reagents which have been customised and designed with a particular analytic task or production process in mind.
Chair: Jim Reid
CEO: Stephane Argivier
Director of Technology and Founder: Dr. Antonio Guerreiro
Chief Commercial Officer: Lowri Cope
Contact: [email protected] | https://www.mip-dx.com/